1. Home
  2. DSGN vs FCCO Comparison

DSGN vs FCCO Comparison

Compare DSGN & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • FCCO
  • Stock Information
  • Founded
  • DSGN 2017
  • FCCO 1994
  • Country
  • DSGN United States
  • FCCO United States
  • Employees
  • DSGN N/A
  • FCCO N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • FCCO Major Banks
  • Sector
  • DSGN Health Care
  • FCCO Finance
  • Exchange
  • DSGN Nasdaq
  • FCCO Nasdaq
  • Market Cap
  • DSGN 208.9M
  • FCCO 190.8M
  • IPO Year
  • DSGN 2021
  • FCCO 1998
  • Fundamental
  • Price
  • DSGN $6.03
  • FCCO $27.92
  • Analyst Decision
  • DSGN
  • FCCO Strong Buy
  • Analyst Count
  • DSGN 0
  • FCCO 2
  • Target Price
  • DSGN N/A
  • FCCO $30.00
  • AVG Volume (30 Days)
  • DSGN 171.5K
  • FCCO 20.8K
  • Earning Date
  • DSGN 11-06-2025
  • FCCO 10-22-2025
  • Dividend Yield
  • DSGN N/A
  • FCCO 2.29%
  • EPS Growth
  • DSGN N/A
  • FCCO 57.01
  • EPS
  • DSGN N/A
  • FCCO 2.23
  • Revenue
  • DSGN N/A
  • FCCO $71,913,000.00
  • Revenue This Year
  • DSGN N/A
  • FCCO $21.83
  • Revenue Next Year
  • DSGN N/A
  • FCCO $28.41
  • P/E Ratio
  • DSGN N/A
  • FCCO $12.52
  • Revenue Growth
  • DSGN N/A
  • FCCO 21.39
  • 52 Week Low
  • DSGN $2.60
  • FCCO $19.46
  • 52 Week High
  • DSGN $7.77
  • FCCO $28.77
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 58.00
  • FCCO 70.45
  • Support Level
  • DSGN $5.65
  • FCCO $27.08
  • Resistance Level
  • DSGN $6.65
  • FCCO $28.77
  • Average True Range (ATR)
  • DSGN 0.51
  • FCCO 0.43
  • MACD
  • DSGN -0.00
  • FCCO 0.03
  • Stochastic Oscillator
  • DSGN 64.27
  • FCCO 57.92

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About FCCO First Community Corporation

First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are; Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.

Share on Social Networks: